Compositions and methods for treating late-onset pompe disease

A method for increasing health-related quality of life of a human individual having a late-onset Pompe disease (LOPD), comprising administering to the individual a pharmaceutical composition comprising an oligosaccharide-protein conjugate and a pharmaceutically acceptable carrier,

• wherein the oligosaccharide-protein conjugate is avalglucosidase alfa,
• wherein the pharmaceutical composition is administered at a dose of about 5 mg/kg to about 40 mg/kg,
• wherein administration of the pharmaceutical composition for 49 weeks to a plurality of individuals results in one or more of the following:
• (a) a decrease in EuroQol 5 Dimensions 5 Response levels (EQ-5D-5L) Mobility score of at least about 0.3;
• (b) a decrease in EQ-5D-5L Self-Care score of at least about 0.1;
• (c) a decrease in EQ-5D-5L Usual Activities score of at least about 0.1;
• (d) a decrease in EQ-5D-5L Pain/Discomfort score of at least about 0.1;
• (e) a decrease in EQ-5D-5L Anxiety/Depression score of at least about 0.1;
• (f) an increase in EuroQol 5 Dimensions Visual Analogue Scale (EQ-VAS) score of at least about 4.3;
• (g) an increase in Rasch-built Pompe-specific Activity (R-Pact) score of at least about 1.3;
• (h) an increase in Patient Global Impression of Change (PGIC) Daily Activities score of at least 4.6;
• (i) an increase in PGIC Disease-Related Symptoms score of at least 4.4;
• (j) an increase in PGIC Ability to Breath score of at least 4.8;
• and
• (k) an increase in PGIC Mobility score of at least 4.4.